Purpose: This study aims to describe the incidence of adverse drug reactions (ADRs) in children receiving antiepileptic drugs (AEDs) and compare ADRs to the individual drugs when given as monotherapy. Method: Paediatric patients (18 years old) were enrolled for this prospective observational study over a 6-month period, between September 2015 and March 2016. Adverse reactions to antiepileptic drugs (AEDs) were elicited at the time of enrolment and after 3 months using the Paediatric Epilepsy Side Effects Questionnaire. Results: A total of 1139 suspected ADRs were reported in 124 participants. Eighteen different AEDs were prescribed. Sixty-six children (53%) were receiving AED monotherapy at the time of recruitment; 34/66 (52%) of whom received new generation AEDs. Levetiracetam was the most frequently prescribed AED (62/124, 50%). When only children receiving AED monotherapy were considered, fatigue, drowsiness, weight gain, dizziness were less likely with levetiracetam (p < .01). Slow thinking and decreased concentration were less likely with levetiracetam or carbamazepine than valproic acid (p < .05). Five patients (four on polytherapy) discontinued AED treatment due to ADRs and 2 had a dose reduction. Conclusions: Levetiracetam and carbamazepine were better tolerated than sodium valproate.
Introduction
Adverse drug reactions (ADRs) are common causes of antiepileptic drug (AED) treatment failure. Up to 25% AED treatment failure has been attributed to ADRs [1, 2] . They can be dose dependent or idiosyncratic. Dose dependent drug reactions worsen with increasing dose and often occur at the initiation of treatment. They are more likely to occur in patients in whom the AED dose has been aggressively escalated and can prevent the attainment of fully effective doses, as well as reduce patients' adherence [2] . Idiosyncratic reactions are unpredictable and often require AED treatment discontinuation [3] . Furthermore, children exposed to multiple AEDs are predisposed to ADRs arising from drug-drug interactions [4, 5] . In about 30% of children, epilepsy is often drug resistant and a change in treatment or addition of new AEDs is indicated [6] .
The goal of epilepsy treatment is seizure control while minimising AED ADRs. A recent UK clinical audit of epilepsy identified lack of sufficient information on ADRs as one of the most common areas for improvement in epilepsy care in children [7] .
Information on AED safety is mainly derived from clinical trials, which are often not designed to provide sufficient drug safety information. Very few prospective AED safety studies [8] [9] [10] have been carried out in children and comparative primary safety studies are lacking.
With the increasing use of new AEDs, there is a greater need to determine and compare the safety of these drugs, especially with the more established old generation drugs. Several of the newer AEDs do not have superior efficacy to the older drugs, and their relative safety, based on the available evidence, is their only comparative advantage [11] . When comparative efficacies are similar, drug choice is often based on local preference or safety profile [12] . While there are several safety studies of the older agents; our knowledge of the safety profiles of the newer drugs is inadequate, mainly because of the relatively small number of patients exposed to some of these drugs. Furthermore, safety evaluation of the new drugs during the immediate post marketing period has also been challenging, as they were mostly approved as add-on treatments and often have restricted use in children.
In this study, the incidence of ADRs in children receiving AED treatment will be described. In addition, the ADRs to the individual drugs as well as the ADRs to the drugs as monotherapy or polytherapy will be compared.
Methods

Participants
Participants were enrolled for this prospective observational study over a 6-month period, between September 2015 and March 2016. All children and adolescents aged 18 years, attending paediatric and teenagers' outpatient epilepsy clinics at the Queens Medical Centre, Nottingham, UK were eligible for inclusion. Only participants receiving one or more AEDs for any type of epilepsy were included in the study. Written informed consent was obtained from parents or guardians of participants less than 16 years old at the time of clinic appointment. However, written consent was sought directly from participants 16 years old and over. The study was approved by the North West -Greater Manchester Central Research and Ethics Committee (Reference number: 12/NW/0868).
Study outcomes
The primary study outcomes were to describe the incidence of ADRs for each AED and compare their toxicity. The secondary outcome was to compare the toxicity of individual AEDs when given as monotherapy and polytherapy. The methodologies for ADR data collection and evaluation will also be piloted for a planned national study.
Data collection and follow-up
Baseline data were recorded, by a member of the research team-OE, on a case report form at the point of recruitment. Data sources were primarily the participants' hospital case notes and electronic records. Data collected included: hospital number, date of birth, gender, weight, AED(s), dose of AED(s), other drugs, type of epilepsy, presence of intellectual disability, e-mail address or postal address and date of visit.
ADRs were elicited at the time of enrolment using the Paediatric Epilepsy Side Effects Questionnaire [13] . The parents or guardians were required to complete this questionnaire if the child was less than 13 years old or had learning difficulties. Older children could complete the questionnaire alone or together with their parents or guardian. It consisted of 19 specific questions on possible ADRs of AEDs and a general enquiry section, which allowed participants to report other ADRs. It also allowed participants or their parents/ guardian to rate the severity of the ADRs using a Likert scale between 1 and 5, with 1 corresponding to low severity and 5 to high severity. The participants were asked to identify and rate any ADR experienced in the preceding 3 months. All participants were sent a follow-up questionnaire electronically or by post, 3 months after enrolment. Thus, a total of 6 months of follow-up data was generated. If the participant or parent did not respond to the initial email, a reminder was sent one week later.
Causality assessment
The relationship between AEDs and suspected ADRs was established using the Liverpool Adverse Drug Reaction Causality Assessment Tool [14] . This algorithm categorises suspected ADRs as unlikely, possible, probable and definite, based on a series of questions on a flow chart. 
Results
Study characteristics
A total of 124 participants were recruited into the study and all completed the first questionnaire. About one quarter of the participants completed the follow-up questionnaire. Of the 98 participants that received the second questionnaire electronically 3 months after recruitment, only 27 (28%) responded. Similarly, 25% (6 participants) of the 24 participants who received the second questionnaire by post responded. Two participants opted not to receive follow-up questionnaires. The majority of the participants were male 56% (n = 70). The median age of participants was 10 years [range: 3 months-18 years; IQR: 6-14]. Twenty-eight participants had intellectual disability (Table 1) . Forty-five patients (36%) were classified as having structural focal epilepsies, 31 (25%) with unclassified focal epilepsies and 18 (15%) with genetic generalised epilepsies ( Table 2 ).
Antiepileptic drug therapy
Eighteen different AEDs were prescribed either as monotherapy or polytherapy. Sixty-six children (53%) were receiving AED monotherapy at the time of recruitment; 34/66 (52%) of whom received new generation AEDs (levetiracetam, lamotrigine, topiramate and zonisamide), and 32/66 (48%) received old generation drugs (sodium valproate, carbamazepine and clobazam). Most children on polytherapy received 2 AEDs (38/58; 66%). Levetiracetam was the most frequently prescribed AED, with 62/124 (50%) children receiving the drug as either monotherapy or polytherapy. More than half (34/62; 53%) of the participants receiving levetiracetam had polytherapy. Sodium valproate (42/124; 34%), clobazam (28/124; 22%), carbamazepine (22/124; 18%) and lamotrigine (19/124; 15%) were the other frequently prescribed AEDs (Fig. 1) . 
Adverse drug reactions
A total of 1139 suspected ADRs were reported over the 6 months of follow-up. Following causality assessment, 49 suspected ADRs were considered unlikely due to any AED and 1090 were possibly or probably attributed to one or more AEDs. No definite causality was identified. 108/124 (86%) of the participants reported at least one suspected ADR. 478 ADRs (42%) were reported in children receiving monotherapy.
A total of 44 different types of suspected ADRs were reported. In addition to the 19 drug-specific ADRs on the questionnaire, 25 other ADR types were elicited by general enquiry (Supplementary Four hundred and sixteen ADRs were reported in 49 of the 62 children who received levetiracetam. 13 of the 62 reported no ADRs with levetiracetam. 264 of the ADRs (63%) were possibly, and 152 (37%) were probably caused by the drug. Both cognitive and behavioural problems were the most commonly reported ADRs. These included attention difficulties (in 47%), decreased concentration (in 44%), aggression (in 45%), and personality change (42%) ( Table 3) .
Three hundred and sixty-six ADRs were reported in 41 of the 42 children who were treated with sodium valproate, 211 (58%) were possibly and 155 (42%) were probably associated with the drug. Fatigue, decreased concentration, attention problems, drowsiness, and poor coordination were each reported in more than half of the children receiving sodium valproate (Table 3) .
One hundred and forty-nine ADRs were reported in 18 of the 22 children on carbamazepine treatment, 105 (70%) were possibly and 44 (30%) were probably attributed to the drug. Fatigue and drowsiness were the most common ADRs and were each reported in more than half of the children (Table 3) .
One hundred and fifty-four ADRs were reported in 18 of the 19 children receiving lamotrigine, 108 (70%) of these were possibly and 46 (30%) were probably associated with the drug. Cognitive problems including, decreased concentration, confusion, drowsiness and poor school performance were each reported in more than half of the children (Table 3) .
Two hundred and sixty ADRs were reported in 27 of 28 children receiving clobazam, 216 (83%) and 44 (17%) of these were possibly and probably related to the drug respectively. Fatigue, drowsiness and slow thinking were the most common ADRs. 
Comparative safety of AEDs
Pre-existing intellectual disability was not significantly associated with any of the ADRs (p > .05). When all treatment regimens were considered, there were significant associations between the type of AED and the risks of drowsiness and decreased concentration. Slow thinking was more frequently reported among children receiving clobazam (64%) than other AEDs. About half of the children receiving sodium valproate and lamotrigine reported slow thinking compared with 32% and 27% of those receiving levetiracetam and carbamazepine respectively (p = .03). The proportion of children receiving clobazam with drowsiness was 64%; while 60%, 59%, 53% and 32% of those receiving valproate, carbamazepine, lamotrigine and levetiracetam respectively reported drowsiness (p = .03). There were no significant differences in the risks of other ADRs among the patients receiving either AED monotherapy or polytherapy (Table 3) .
When only children receiving AED monotherapy were considered, there were significant associations between the type of AED and the risks of fatigue, drowsiness, weight gain, dizziness, slow thinking and decreased concentration. Only 25% of children receiving levetiracetam reported fatigue, while 82% of those receiving carbamazepine and 71% of those receiving sodium valproate did (p = .001). Similarly, 18% of children receiving levetiracetam monotherapy were drowsy compared with 49% and 62% of those receiving carbamazepine and sodium valproate respectively (p = .001). 7% of children receiving levetiracetam reported weight gain and dizziness; while 27% of those receiving carbamazepine did. The proportion of children receiving sodium valproate with weight gain and dizziness were 48% and 38% respectively (p = .005 and .01 respectively). About two-third of children receiving sodium valproate reported slow thinking compared with 29% and 27% of those receiving levetiracetam and carbamazepine respectively (p = .03). Similarly, 86% of children receiving sodium valproate reported decreased concentration compared with 46% and 36% of those receiving levetiracetam and carbamazepine respectively (p = .01) ( Table 4) . Table 3 Children reporting ADRs with all regimens of sodium valproate, levetiracetam, clobazam, carbamazepine, and lamotrigine.
Adverse reaction
Sodium valproate (n = 42, %) Levetiracetam (n = 62, %) Clobazam (n = 28, %) Carbamazepine (n = 22, %) Lamotrigine (n = 19, %) P value 
AED discontinuation and dose reduction due to ADRs
Five patients (one monotherapy) discontinued AED treatment due to ADRs and 2 (one monotherapy) had a dose reduction. Three of these were receiving levetiracetam (3/62; 5%), 2 sodium valproate (1/42; 2%) 1 each received carbamazepine (1/22; 5%) and topiramate (1/12; 8%). No one discontinued or had a dose reduction reported due to clobazam.
Two children had levetiracetam withdrawn due to behavioural problems (2/62; 3%), the third for nausea and excessive salivation.
A 3-year-old girl receiving topiramate and sodium valproate for epileptic encephalopathy (with previous infantile spasms), had topiramate withdrawn because of weight loss (from 75th percentile to 25th percentile over one year).
An 11-year-old girl stopped sodium valproate treatment following abnormal thyroid function test results. In addition, she reported episodes of dizziness, double vision and headaches. Her serum sodium valproate level was 145.1 mg/L (target range 100 mg/L).
Two children had AED dose reduction following ADRs. A 12-year-old girl receiving 36 mg/kg/day of sodium valproate for focal epilepsy had dose reduction to 28 mg/kg/day as a result of behavioural problems and drowsiness. Another 7-year-old girl on carbamazepine and sodium valproate treatment for focal epilepsy had carbamazepine dose reduced from 6.5 mg/kg/day to 5.5 mg/ kg/day due to worsening episodes of drowsiness, constipation and abdominal pain
Discussion
Levetiracetam, sodium valproate, carbamazepine and lamotrigine were the most commonly prescribed AEDs in this study, with levetiracetam constituting half of all prescribed AEDs in these children. About 80% of children receiving AEDs reported at least one ADR. Neurological ADRs, mainly cognitive and behavioural disorders, were the most common problems. The high prevalence of neurological ADRs has also been reported in other studies [15] and causality evaluation is often difficult because the symptoms can also be features of epilepsy and its comorbidities [16, 17] .
There were significant associations between the type of AED and the risks of fatigue, drowsiness, weight gain, dizziness, slow thinking and decreased concentration. This study showed levetiracetam and carbamazepine monotherapy to be better tolerated than sodium valproate in children. Although clinical studies have shown adjunctive levetiracetam to be as effective and safe as other AEDs for paediatric seizures [18] [19] [20] , there is currently insufficient evidence of its safety as a monotherapy agent. There are few levetiracetam monotherapy studies in children, hence, it does not currently have marketing authorisation for use alone in those <16 years old [21] . A small prospective study involving 10 children with focal and generalised epilepsies however, found levetiracetam monotherapy to be safe and effective [22] . The efficacy and safety of levetiracetam monotherapy has also been established in some retrospective studies [23, 24] . Similar to the findings of this study, a systematic review of the safety of levetiracetam in children also reported significantly lower ADR rates with levetiracetam monotherapy than polytherapy. More treatment discontinuation occurred among those receiving polytherapy and behavioural problems were the most common reasons for treatment discontinuation [25] . In our study, all the patients that discontinued levetiracetam treatment had been taking polytherapy.
More than half of AED prescriptions in this study were monotherapy. This is similar to reports from large database studies [26, 27] . Between 30% and 40% of patients do not respond to the first AED and often subsequently receive polytherapy [28, 29] . This is a pilot study and the patient sample size is small, therefore these results may not all be truly representative. Another limitation is that some of the items on the questionnaire may not be appropriate for younger participants, who may be unable to express themselves. We believe many more ADRs were elicited than in previous studies, because of the active questioning about specific ADRs with the drug specific questionnaires. For example, a systematic review of lamotrigine safety in children showed an incidence rate of memory problems, loss of concentration, and personality change of less than 0.3% [30] compared to 63%, 37% and 27% respectively in this study. Similarly, lower incidences of ADRs were reported in another levetiracetam systematic review than this study [25] . ADR screening with questionnaires or checklists often results in overestimation [2, 31] . This phenomenon, the anchoring effect, has been described in behavioural psychology [32] .
The elicitation method used is however unlikely to affect the comparative analyses of the drugs, since all drugs were subject to the same bias. With causality assessment algorithms, it was difficult to determine definite causality because of the need to re-administer the drugs after initial withdrawal. The alternative basis for a definite attribution was if the patient had a previous similar reaction to the drug. These two scenarios are rarely seen in clinical practice and this was never the case for any patient in this study. However as with the frequency of ADRs, this should not affect the relative risk of ADRs on different AEDs.
In conclusion, both levetiracetam and carbamazepine were better tolerated than sodium valproate.
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